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Effective quality assurance is essential in any screening programme. This article provides a unique 
insight into key quality indicators of five rounds of the first population-based colorectal cancer 
screening programme implemented in Spain (2000–2012), providing the results according to the 
type of screening (prevalent or first screen and incident or subsequent screen) and test (guaiac or 
immunochemical). The total crude participation rate increased from 17.2% (11,011) in the first round 
to 35.9% (22,988) in the last one. Rescreening rate was very high (88.6% in the fifth round). Positivity 
rate was superior with the faecal immunochemical test (6.2%) than with the guaiac-based test (0.7%) 
(p < 0.0001) and detection rates were also better with the immunochemical test. The most significant 
rise in detection rate was observed for high risk adenoma in men (45.5 per 1,000 screened). Most 
cancers were diagnosed at an early stage (61.4%) and there was a statistically significant difference 
between those detected in first or subsequent screening (52.6% and 70.0% respectively; p = 0.024). The 
availability of these results substantially improves data comparisons and the exchange of experience 
between screening programmes.
Screening for early detection of colorectal cancer (CRC) and its premalignant precursors has consistently demon-
strated efficacy in reducing disease-specific mortality1. The European Union proposed faecal occult blood testing 
(FOBT) as the standard for CRC screening2,3 at about the same time as evidence supporting CRC was reported 
in a Cochrane review4.
During the last years, organized CRC screening programmes have been increasingly adopted throughout 
Europe5 and the immunochemical test (FIT) has emerged as a good option for screening6.
Since screening programmes invite healthy people with no symptoms, it is crucial to achieve an effective qual-
ity assurance to guarantee that the benefits of screening (better survival and quality of life) outweigh the harms 
(false negative result, false positive, complications related to colonoscopy as perforation or lower gastrointestinal 
bleeding)7,8. To that effect, screening programmes have the responsibility to ensure that quality is optimized in all 
ways: high quality, safe procedure and a satisfactory experience.
The European Union has proposed Key Performance Indicators for quality assurance and to monitor and 
compare the results of the screening programmes9.
In Spain, some regions implement and manage CRC screening programmes10,11. In 2000, Catalonia was the 
first region to launch a population-based CRC screening programme using FOBT in Hospitalet de Llobregat, a 
city of about 256,000 inhabitants in the metropolitan area of Barcelona12.
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The objective of this study was to evaluate the five rounds (2000–2012) of the CRC screening programme and 
to identify those quality indicators that require improvement.
Methods
Five rounds have been performed in the Catalan CRC biennial screening programme, from February 2000 to 
November 2012. Despite an intended 2-year interval between rounds, delays occurred in the first two rounds due 
to programming and management constraints. The screening programme began as a pilot with continuous mon-
itoring of results and strategic modifications to accomplish the time intervals and other quality indicators. One 
of the most important modifications was the use of a more advanced informatics system and the incorporation 
of personal dedicated exclusively to the screening programme. Data to assess the screening process was obtained 
from the screening programme registry, which is a specific informatic data system only available for professionals 
of the programme. This registry integrates data from different healthcare informatics systems but the information 
is not accessible to everyone.
Population. The target population included about 65,000 men and women aged 50–69 who were residents in 
the screening area, Hospitalet de Llobregat, a municipality to the immediate southwest of Barcelona. L’Hospitalet 
is the second largest city in Catalonia and one of the most densely populated cities in the European Union. About 
2.2% of the population are illiterate, 11.9% have no education and the 16.3% have elementary education13.
Demographic data on this population was gathered from the Central Registry of Insured (Primary Healthcare 
Information System)14. L’Hospitalet is divided into 12 Health Care Centres and each individual is uniquely allo-
cated to a general practitioner in one of these centres.
Exclusion criteria. Subjects who did not meet the inclusion criteria for CRC screening were excluded 
according to the following criteria: personal history of CRC or adenomas, familial CRC cancer, inflammatory 
bowel disease, colonoscopy in the previous 5 years or FOBT in the previous 2 years, terminal disease or severe 
disabling condition. Subjects with an invalid mailing address and removals from the screening area registry were 
also excluded because they could not be invited to screening.
Invitation process. Eligible subjects were invited by a personal letter offering a test completely free. A bro-
chure with information regarding CRC and the screening process was sent with the invitation letter. The invita-
tion was sent sequentially along the 12 Health Care Centres. A reminder letter was sent out if no response was 
obtained after six weeks of the initial invitation.
FOBT (screening test). Guaiac-based faecal occult blood test (gFOBT) was the only test used in the first 
three rounds (Hema-screenTM, immunostics.inc). In the fourth round, the FIT (OC Sensorμ , Palex) was partially 
introduced and offered to 12,707 individuals to assess its feasibility and acceptability. The gFOBT was offered to 
the rest of the target population (50,227). According to the good results with FIT, the Catalan Cancer Strategy 
decided that this screening test would be used throughout Catalonia. So in the fifth round the FIT was the unique 
test used.
Participants with gFOBT collected two samples of faeces from each of three consecutive stool specimens 
with no dietary restriction. The possible results of the gFOBT were 1) negative: zero out of six positive spots; 
2) positive: five or six positive spots in a first gFOBT or one to six positive spots after a weak positive gFOBT; 
3) weak positive: blood detected in one to four spots. Those participants were asked to perform a second gFOBT 
in this case with dietary restriction and, if any spot was positive, a colonoscopy was offered without further 
testing. In contrast, when all six spots were negative on the second test, a third gFOBT was requested, also with 
dietary restriction, to confirm a negative result; 4) inconclusive: expired samples (negative result with more than 
14 days between faeces collection and its analysis), lack of information in the kit (personal identification number, 
date of faeces collection), or any technical failure or improper performance of the test. In any of these cases, a new 
gFOBT was also requested.
Dietary restriction consisted in a diet without foods containing peroxidase activity, such as uncooked vegeta-
bles or red meat, three days before the collection of samples.
Participants with FIT collected only one sample of faeces from one bowel movement. The cut-off was 100 ng/
mL (20 μ g Hb/g faeces). The results were categorized as positive (≥ 100 ng/mL), negative (< 100 ng/mL) and 
inconclusive (the same reasons as gFOBT).
Individuals with inconclusive or negative final results were informed by mail. If there was no medical con-
traindication, subjects with a positive result were referred for colonoscopy and were offered an appointment date 
by phone.
Colonoscopy (confirmatory examination). A preoperative evaluation was routinely required (haemo-
stasis test and electrocardiogram for all individuals and a chest x-ray only for individuals older than 64 years or 
with a chronic disease). Colonoscopies were performed with sedation on an outpatient basis at the Endoscopy 
Units of the county Hospitals by expert endoscopists using a specific afternoon agenda. Four days prior to colo-
noscopy, patients were phoned to remind them about the appointment to give instructions for the bowel prepa-
ration which was provided by primary health centres, either polyethylene glycol or sodium phosphate. Non-split 
dosing was used.
For those who chose to perform colonoscopy in a private clinic out of our programme, a postage paid envelope 
was provided in order to receive a copy of the colonoscopy report.
Follow-up of colonoscopy results. If no adenomatous polyps were found, subjects were recorded to be 
invited for screening again after 10 years (provided that they still meet the inclusion criteria).
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Any detected polyp was described and removed when endoscopically possible and sent for pathology review. 
Number, size (mm), morphology (pedunculated, sessile or flat) and location (rectum, sigmoid, descending, trans-
verse, ascending or caecum) were documented. The follow-up of these lesions was transferred to the general 
practitioner or to the gastroenterology service.
For incomplete colonoscopies, patients were offered a new attempt of colonoscopy or another diagnostic 
exploration. Subjects with cancer or polyps too large or complicated to be removed endoscopically were referred 
to surgery. Major immediate complications were also documented (perforation, post-polypectomy bleeding 
involving transfusion or hospitalisation of at least 24 hours, and death within 30 days).
Neoplasm classification. The histological classification of polyps and cancer was based on World Health 
Organization criteria15. Low-risk adenomas (LRA) were 1 or 2 lesions smaller than 10 mm, showing a tubu-
lar histology and low-grade dysplasia. High-risk adenomas (HRA) were defined as either adenomatous polyps 
≥ 10 mm, or more than 2 adenomas, any adenoma with a tubulovillous or villous histology, or high-grade dys-
plasia. Carcinoma in-situ was classified as HRA. Advanced neoplasm included invasive carcinoma or HRA. All 
detected cases of invasive carcinoma were referred to the multidisciplinary CRC committee for appropriate oncol-
ogy treatment. Tumours were staged according to the TNM system16.
During the study period, the European Guideline for Quality Assurance in Colorectal Cancer Screening and 
Diagnosis9 was published incorporating the intermediate risk adenoma (IRA) as a new category. Before its pub-
lication IRA was included into HRA. For the purpose of this study, we have maintained the initial risk classifica-
tion. Nevertheless, recommendations for surveillance colonoscopies were made according to the most updated 
guidelines.
Key Performance Indicators. In order to monitor the programme, we developed a series of key perfor-
mance indicators (KPIs), including organizational (structural), process, and impact (short term outcomes) indi-
cators (Table 1).
KPIs were analyzed by sex, age group and type of screening (prevalent or first screen and incident or subse-
quent screen) and type of screening test (gFOBT or FIT).
KPIs were compared with standard values published in the European Guideline9. The Catalan Advisory Group 
for Cancer Screening17 also edited a guideline following the principles of the European Guidelines. This lat-
ter added a new indicator (rescreening) and changed the standard value of 2 KPIs (time to colonoscopy and 
early-stage cancers). Definitions and measures of KPIs are shown in the Table 2.
Table 1.  Acceptable standard value of the key performance indicators for colorectal cancer screening 
and results of the fifth round. Organiz: Organizational. gFOBT: guaiac faecal occult blood test; FIT: faecal 
immunochemical test. ‡Improvement: results below the standard value; Acceptable: results up to 10% the 
standard value; Outstanding: ≥ 10% standard value. *This indicator is not included in the first edition of the 
European guidelines for quality assurance in colorectal cancer screening and diagnosis, 2011. **Acceptable 
standard value considered by the Catalan Advisory Group for Cancer Screening for the time interval to 
colonoscopy is > 90% of colonoscopies performed within 60 days (instead of 31) and for the early stage cancers 
is ≥ 70% (instead of favourable). ***Data obtained from randomized controlled trials. †Data obtained from 
population-based programmes. na: not data available.
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We created a rating of each KPI according to its result: “outstanding” when the indicator exceeded 10% the 
reference value; “acceptable” when the indicator exceeded up to 10% of the standard, and “needs for improvement”, 
when the indicator was below the standard.
Type Indicator Screening measure
ORGANIZATIONAL
Coverage rate by invitation (%) = A2/A1
A1 = Eligible.
Total number of people eligible for screening according to the programme 
policy.
A2 = Invited.
Total number of people who received an invitation for screening according to 
the programme policy.
Participation (%) = B/A2
B = Tested.
Total number of people who have used and returned a FOBT kit irrespective of 
result. This includes people with inadequate/incomplete results. Note that each 
person is counted once regardless of the number of tests performed.
Rescreening (%) = B/A3
A3 = Invited & previous screened.
Total number of people invited for screening who participated in a previous 
round.
Time to FOBT outcome (days) = C2-C1
C1 = Date of completion of FOBT.
C2 = Date of receipt of results by the subject.
To calculate this time interval we have used indirect measures. We used 
the date of the first stool sample and the date of sending the letter about the 
screening results.
Time to colonoscopy (days) = D2-D1
D1 = Date of positive FOBT result.
D2 = Date of colonoscopy after positive screening.
We used the date recoded by the laboratory after analysing the FOBT and the 
date when the colonoscopy was performed.
PROCESS
Inadequate FOBT (%) = E2/B
E1 = Adequately tested.
Total number of people who have returned a FOBT and achieved a conclusive 
result (positive or negative).
E2 = Inadequately tested.
Total number of people who have returned an inadequate FOBT (spoilt kit/
technical failure or weak positive) and did not achieve a conclusive result.
FOBT Positivity (%) = F/E1
F = Positive FOBT.
Total number of people who have a positive/abnormal result with FOBT.
Referral to colonoscopy (%) = G/F
G = Referred to colonoscopy.
Total number of people presenting with a positive FOBT and referred for 
colonoscopy.
Colonoscopy Compliance (%) = H/G
H = Diagnostic/therapeutic colonoscopy.
Total number of people who have undergone a colonoscopy, including those 
whose colonoscopy was inadequate/ incomplete. Note that each person is 
counted once regardless of the number of colonoscopies which were per-
formed.
Caecal intubation (%) = K/ H
K = Caecal intubation (completion).
Total number of complete colonoscopies (complete intubation of the colon and 
to carefully inspect the mucosa during withdrawal).
Colonoscopic complications (‰) = L/H
L = Severe complications requiring hospitalizations.
Total number of severe complications such as hospitalisation within 30 days 
due to serious haemorrhage involving transfusion, or due to perforation, vagal 
syndrome or peritonitis-like syndrome as a consequence of follow-up colonos-
copy after positive screening.
PPV LRA (%) = M1/H
M1 = LRA.
Total number of people whose pathological specimens removed at endoscopy 
or surgery have been reported by a pathologist to be smaller lesions (≤ 10 mm) 
showing a tubular histology and low-grade dysplasia from all the people with 
colonoscopy performed.
PPV HRA (%) = M2/H
M2 = HRA.
Total number of people whose pathological specimens removed at endoscopy 
or surgery have been reported by a pathologist to be either adenomatous pol-
yps larger or equal than 10mm, or more than 2 adenomas, any adenoma with a 
tubolovillous or villous histology, or high-grade dysplasia, from all the people 
with colonoscopy performed.
PPV Cancer (%) =  N/H
N = Cancers.
Total number of people diagnosed with colorectal cancer by or as a direct result 
of the screening programme, from all the people with colonoscopy performed.
Continued
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Statistical methods. Rates and proportions were compared with Chi-square tests and logistic regres-
sion models. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to estimate the differences. A 
p-value ≤ 0.05 was considered statistically significant.
Ethics. Our CRC screening programme, like all Spanish population-based screening programmes, follows 
the Public Health laws and the Organic Law on Data Protection. The screening programme accomplishes the 
specific protocol based on the existing guidelines; the protocol was approved by the Ethics Committee of the 
University Hospital of Bellvitge. Moreover, informed consent was obtained from all the participants who under-
went a colonoscopy.
Results
Throughout five rounds, 114,559 people were invited, 37,953 participated at least once and 86,320 FOBT were 
performed. The KPIs of the five screening rounds are shown in Table 3.
Organizational indicators. The coverage invitation rate was almost 100% in the five rounds. The pro-
gramme invited the entire eligible population. In less than 1.5% the letter did not arrive due to errors in the 
address.
The total crude participation rate increased from 17.2% in the first round to 35.9% in the last one which, 
though represents a statistically significant increment (p < 0.0001), was still far from the standard minimum 
desirable value (45%). Participation rate was consistently higher in women than men (p < 0.001) and in those 
between 60 and 69 years old, except for the first round (Fig. 1). Rescreening rate exceeded 80.0% in all rounds.
The standard of time to FOBT result was not achieved in the third round and time to colonoscopy did not 
reached the standard value in any round. Particular emphasis should be placed on FIT with only 36.4% of colo-
noscopies managed in the correct time interval in the fourth round, but reaching 61.7% in the fifth.
Process indicators. Positivity rate was superior with FIT than gFOBT (p < 0.0001). Independently of the 
test used, subsequent screened had lower positivity rates than 1st screened with the exception of FIT users in the 
4th round, where first and subsequent screen had the same positivity rate.
In all rounds the positivity rate was higher in the oldest group (60–69 years) and significantly higher in men 
than in women (p < 0.05).
Inconclusive FOBT rate decreased significantly in every round mainly in subsequent screenees (Table 3). The 
most common reason for coding an inconclusive FOBT was the incomplete information provided with the kit.
More than 95% of positive FOBT were referred for colonoscopy. The main reason for not recommending 
the exploration was having had a recent one. The majority of people accepted the colonoscopy as a diagnostic 
exploration. Therefore, colonoscopy compliance was one of the best process indicators, above the standard value 
(> 85%) in all rounds.
The caecal intubation rate was within the range set by the European guideline as desirable. The most common 
reason for not reaching the caecum was stenosis.
The complication rate remained fairly constant at around 10 per 1,000 over time, except in the second round 
where no serious complications were reported, and in the fifth round, where the lowest rate was obtained (8.7 per 
1,000). Seventy-nine percent of complications were post-polypectomy bleeding.
The Positive Predictive Value (PPV) for HRA was higher in the first screening compared to subsequent 
screening, except in the fifth round. PPV for cancer was also superior in the first screening except in the fourth 
round regardless of the test used (Table 3). The numbers, however, are small and no significant differences were 
observed.
Table 4 shows the results by type of test used independently of the round. We can observe that the PPV for 
advanced neoplasia (HRA or cancer) was higher in men than in women in all cases. When only gFOBT was used, 
the PPV for HRA and cancer were better in subsequent screening, except the PPV for HRA in women. Contrary, 
Type Indicator Screening measure
IMPACT
LRA detection rate (‰)= M1/E1
Total number of people whose pathological specimens removed at endoscopy 
or surgery have been reported by a pathologist to be smaller lesions (≤ 10 mm) 
showing a tubular histology and low-grade dysplasia from all the people with a 
FOBT adequately performed.
HRA detection rate (‰)= M2/E1
Total number of people whose pathological specimens removed at endoscopy 
or surgery have been reported by a pathologist to be either adenomatous pol-
yps larger or equal than 10mm, or more than 2 adenomas, any adenoma with a 
tubolovillous or villous histology, or high-grade dysplasia, from all the people 
with a FOBT adequately performed.
Cancer detection rate (‰) = N/E1
Total number of people diagnosed with colorectal cancer by or as a direct result 
of the screening programme, from all the people with a FOBT adequately 
performed.
Early- stage cancers (%) =  O/N
O = Early- stage cancers (I and II).
Total number of screen-detected cancers that were staged as I-II using the 
international TNM classification.
Table 2.  Colorectal cancer screening measures and indicators*. *Based on the European Guidelines for 
Quality Assurance in Colorectal Cancer Screening and Diagnosis – First Edition. FOBT: faecal occult blood test; 
LRA: low risk adenoma; HRA: high risk adenoma.
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when FIT was the unique test used, the PPV was higher in first screening both in men and women. The results in 
the combined group can be considered similar to those obtained for FIT in first screenings.
Impact indicators. An increase in detection rate was noticed with FIT. Both HRA and cancer detection 
rates in men and women were higher in first screening compared to subsequent screening (Table 4). The detec-
tion rate was much higher with FIT than with gFOBT and always higher in men than in women. In men, the 
advanced neoplasm detection rate in first screening with gFOBT and FIT was 10.7 and 48.0 per 1,000, respec-
tively. Subsequent screening detection rates in men were 5.1 per 1,000 using gFOBT and 14.2 per 1,000 with FIT.
As shown in Fig. 1, the most significant rise in detection rate was observed for HRA in men who used FIT 
(45.5 per 1,000 screened) and in people aged more than 60 years old (31.3 per 1,000 screened). Cancer detection 
rate also showed an increase but less than HRA.
Overall, 61.4% of cancers were diagnosed at an early stage, with a statistically significant difference between 
those detected in first or subsequent screening (52.6% and 70.0%, respectively; p = 0.024).
Taking into account the results of the last round, most indicators reached or exceeded the acceptable standard 
value (Table 1).
1st ROUND 2nd ROUND 3rd ROUND 4th ROUND 5th ROUND
gFOBT gFOBT gFOBT gFOBT FIT
n (%) n (%) n (%) n (%) n (%) n (%)
ORGANIZATIONAL
  Coverage by 
Invitation 63,880 (99.6) 66,534 (99.8) 65,142 (99.6) 50,227 (99.6) 12,707 (99.8) 64,117 (98.6)
 Participation 11,011 (17.2) 14,818 (22.3) 17,742 (27.2) 15,143 (30.2) 4,618 (36.3) 22,988 (35.9)
 Rescreening * 7,424 (73.2) 10,415 (87.0) 10,382 (87.3) 3,210 (89.7) 14,623 (88.6)
  Time to 
FOBT result 
(%≤15days)
** ** 16,652 (84.7) 14,360 (89.1) 3,938 (97.2) 21,581 (97.7)
  Time to 
Colonoscopy 
(%≤60days)
252 (75.4) 77 (72.0) 127 (70,9) 83 (88,3) 96 (36.4) 696 (61.7)
PROCESS
 Colonoscopy
   Referral to 
Colonos-
copy
372 (100.0) 123 (100.0) 182 (96.3) 99 (96.1) 280 (97.6) 1,238 (95.5)
  Compliance 334 (89.8) 108 (87.8) 180 (98.9) 96 (97.0) 271 (96.8) 1,147 (92.3)
   Caecal 
intubation 308 (92.2) 100 (92.6) 164 (91.1) 93 (96.9) 255 (94.1) 1,122 (97.8)
   Severe Com-
plications 3 9.0‰ 0 0.0‰ 2 11.1‰ 1 10.5‰ 3 11.1‰ 10 8.7‰
1st Scr. 1st Scr. Subs. 1st Scr. Subs. 1st Scr. Subs. 1st Scr. Subs. 1st Scr. Subs.
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
  Inconclusive 
FOBT 383 (3.5) 360 (4.9) 276 (3.7) 265 (4.1) 301 (2.7) 92 (2.1) 107 (1.0) 32 (2.5) 18 (0.5) 219 (2.9) 62 (0.4)
 Positivity 372 (3.5) 79 (1.1) 44 (0.6) 74 (1.2) 115 (1.1) 39 (0.9) 64 (0.6) 78 (6.3) 209 (6.3) 509 (7.0) 788 (5.1)
 Positive Predictive Value
   Low Risk 
Adenoma 22 (6.6) 5 (7.1) 2 (5.3) 4 (5.6) 9 (8.3) 2 (5.6) 4 (6.7) 7 (9.3) 17 (8.7) 65 (14.9) 119 (16.8)
   High Risk 
Adenoma 79 (23.7) 33 (47.1) 9 (23.7) 31 (43.7) 28 (25.7) 18 (50.0) 27 (45.0) 38 (50.7) 84 (42.9) 195 (44.6) 320 (45.1)
  Cancer 23 (6.9) 9 (12.9) 4 (10.5) 12 (16.9) 15 (13.8) 4 (11.1) 9 (15.0) 4 (5.3) 16 (8.2) 27 (6.2) 36 (5.1)
IMPACT
 Detection Rate (‰) (‰) (‰) (‰) (‰) (‰) (‰) (‰) (‰) (‰) (‰)
   Low Risk 
Adenoma 22 (2.1) 5 (0.7) 2 (0.3) 4 (0.6) 9 (0.8) 2 (0.5) 4 (0.4) 7 (5.6) 17 (5.1) 65 (8.7) 119 (7.7)
   High Risk 
Adenoma 79 (7.4) 33 (4.7) 9 (1.3) 31 (5.0) 28 (2.6) 18 (4.3) 27 (2.5) 38 (30.5) 84 (25.3) 195 (26.1) 320 (20.6)
  Cancer 23 (2.2) 9 (1.3) 4 (0.6) 12 (1.9) 15 (1.4) 4 (1.0) 9 (0.8) 4 (3.2) 16 (4.8) 27 (3.6) 36 (2.3)
(%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
  Early Stage 
Cancers 13 (56.5) 6 (66.7) 3 (75.0) 5 (41.7) 9 (60.0) 1 (25.0) 7 (77.8) 2 (50.0) 11 (64.7) 15 (55.6) 26 (72.2)
Table 3.  Results of the Colorectal Cancer Screening Key Performance Indicators per round. gFOBT: guaiac 
faecal occult blood test; FIT: immunochemical faecal occult blood test. *not applied; **not available. Scr: screen; 
Subs: subsequent.
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Discussion
This article provides a unique insight into KPI of the first five rounds of the earliest population-based CRC screen-
ing programme implemented in Spain. At the beginning, the results were poor for nearly all indicators. In the last 
round, only 4 indicators did not meet the European standards9 (participation, positivity, time to colonoscopy and 
initial stage cancers).
Participation rates in other Europeans CRC screening programmes with more than one round were higher 
than ours. The English, Scottish and French programmes reached a participation over 50% in their first round18–20. 
Surprisingly, in both the UK and France the participation fell in the 2nd round, which the authors attributed 
to a greater publicity in the first round when the piloting was launched. In other Spanish programmes, the par-
ticipation rate was also greater than in ours21,22. In Hospitalet de Llobregat participation in the first round was 
only 17.2% but has increased progressively until 35.9% in the fifth round. Despite this poor participation, never 
reaching the standard of > 45%9, it is noteworthy that the rescreening rate was outstanding (88.6% in the fifth 
round), which could suggest that participants are highly satisfied and accept the screening programme. Albeit 
participation rate when FIT was used was higher than with gFOBT (36.3% vs 30.2%), the rise was within the 
expected limits.
Like the vast majority of programmes, participation was higher among women than men. This sex gap in par-
ticipation rates widened over time, being in the final round 37.7% and 33.9% respectively (p < 0.001).
As expected, the elderly were more likely to accept screening than younger population, except in the first 
round, and as in the case of sex, the difference increased along rounds.
We believe that the low participation rate reflects a lack of information of the complete screening process. 
Massive diffusion campaigns are needed to inform the general population about the high frequency of CRC in 
our setting, its primary risk factors and prevention measures, and the risks and benefits of taking part in screening 
programmes. The low participation could also be due to the high percentage of people with no education or pri-
mary education, comparing with Barcelona (the biggest Catalonian city), which has better participation rates but 
also lower illiteracy rates12,23. Finally, another point to consider for increasing participation rates is the migrant 
population living in the territory. Creating multilingual materials could be an additional strategy in areas with 
high migration rates.
FIT has many advantages with respect to gFOBT. Only one stool sample is necessary, no dietary restrictions 
are needed, the method for collecting is easier and less disgusting, it is possible to establish the most appropriate 
threshold level and, it has better sensitivity for detecting neoplasia24–27. On the other hand, the warm climate and 
the haemoglobin degradation over time may influence the FIT outcome, which would make it necessary to refrig-
erate the stool sample once it has been collected28,29.
The main reason for coding an inconclusive result for gFOBT and FIT was an improper performance of the 
test and the lack of the date of faeces collection, respectively. Our programme takes into account the date of col-
lection of faeces due to the established relation with the higher degradation of haemoglobin with time28,29. So if 
a stool sample was collected more than fourteen days before its analysis and the result was negative, a new FOBT 
was required.
Positivity rate was the expected: higher positivity among men than in women and in the older group com-
pared to the youngest. Positive rates with FIT were more than 7 times higher than gFOBT. Our results are in con-
sonance with those published in the literature from screening programmes16,30 using the same FIT. Nevertheless, 
despite the forecast for the increase of diagnostic colonoscopies required by FIT, we were not able to carry them 
out within the appropriate time interval.
Colonoscopy compliance is a key indicator to consider when evaluating the effectiveness of the programme. In 
the first two rounds, despite acceptance being within the acceptable standard, it did not reach 90% as in following 
rounds. This might be due to the monitoring of people who had to undergo a colonoscopy done by the technical 
office. An average of 3 phone calls was made as a reminder of the appointment for the colonoscopy and the need 
of previous preparation.
More than 90% of colonoscopies reached the caecum. Caecal intubation is associated with sedation, since 
the participant’s welfare makes it possible to have more often an entire exploration and bowel preparation31. The 
Figure 1. Participation and Detection Rates by sex (a) and age group (b).
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need for completeness is based on the finding that an important number of CRC (near 30%) are located in the 
proximal colon. Caecal intubation rate is affected by a number of factors including bowel cleansing. Our adequate 
bowel cleansing rate was one of the highest reported in a screening programme32–34. We probably obtained this 
excellent result due to the extensive work done by the administrative staff who widely explained the whole process 
for a good bowel-cleansing and made a telephone reminder some days previous to the colonoscopy appointment. 
Inadequate bowel preparation not only limits the visibility of the mucosa and prolongs caecal intubation and 
withdrawal time, but it also leads to a shorter interval for the next exam. Nevertheless, the quality of bowel cleans-
ing is a subjective measure and efforts to increase reproducibility and validity are needed35.
Complication rates should be interpreted carefully. The perforation rate considering the small number of colo-
noscopies performed, can largely vary from round to round and it is not considered a stable indicator. According 
to the European Guideline9, major complications (perforation and bleeding) occur in 0–3 per 1,000 colonoscopies 
in a high-quality CRC screening programme using colonoscopy as a primary screening test. On the other hand, 
the standard regarding major complications in people attending FOBT screening (as occurs in our programme) 
is 5–16 per 1,000 subjects undergoing colonoscopy. In that case the complication rate is higher because the colo-
noscopy is performed in individuals with a positive FOBT (screening test), which makes it more probable that 
they will have a neoplastic lesion and consequently more likely to have a complication derived from its removal.
Complication rate might be underestimated. We believe it is necessary to establish a system to detect com-
plications after the patient has left the endoscopy department. Screening programmes are working to try to 
get as much information as possible, including minor complications that may arise before, during or after the 
colonoscopy.
The PPV improved with rounds, being clearly better in first than subsequent screenees. This indicator is closely 
linked to the false positive rate. False-positive tests lead to discomfort, costs and risks from additional diagnostic 
and therapeutic procedures. So it is important to identify factors associated with false-positive results. In our 
previous work we found that the risk of a false positive result increased with successive screening participations 
(OR = 1.72; 95% CI:1.20–2.46)36. Potential interference of drug intake such as antiplatelet and anticoagulation 
therapy and non-steroidal anti-inflammatory drugs has been reported, as well as the presence of haemorrhoids, 
with even contradictory results37–40.
Tested
gFOBT gFOBT+FIT FIT
First Subsequent Overall Subsequent First Subsequent Overall
n n n n n n n
 Male 13,261 13,238 26,499 7,797 3,959 352 4,311
 Female 15,940 16,275 32,215 10,223 4,793 482 5,275
29,201 29,513 58,714 18,020 8,752 834 9,586
Positive FOBT & Di-
agnostic Endoscopy n n n n n n n n
 Male 278 113 391 508 316 16 332
 Female 233 94 327 368 196 14 210
511 207 718 876 512 30 542
Endoscopy Result n PPV DR n PPV DR n PPV DR n PPV DR n PPV DR n PPV DR n PPV DR
 Male
   Normal & 
polyps 120 43.2% 9.0‰ 36 31.9% 2.7‰ 156 39.9% 5.9‰ 119 23.4% 15.3‰ 76 24.1% 19.2‰ 7 43.8% 19.9‰ 83 25.0% 19.3‰
   Low Risk 
Adenomas 16 5.8% 1.2‰ 9 8.0% 0.7‰ 25 6.4% 0.9‰ 86 16.9% 11.0‰ 49 15.5% 12.4‰ 4 25.0% 11.4‰ 53 16.0% 12.3‰
   High Risk 
Adenomas 111 39.9% 8.4‰ 47 41.6% 3.6‰ 158 40.4% 6.0‰ 273 53.7% 35.0‰ 166 52.5% 41.9‰ 5 31.3% 14.2‰ 171 51.5% 39.7‰
  Cancer 31 11.2% 2.3‰ 21 18.6% 1.6‰ 52 13.3% 2.0‰ 30 5.9% 3.8‰ 25 7.9% 6.3‰ 0 0.0% 0.0‰ 25 7.5% 5.8‰
   Advanced 
Neoplasm 142 51.1% 10.7‰ 68 60.2% 5.1‰ 210 53.7% 7.9‰ 303 59.6% 38.9‰ 191 60.4% 48.2‰ 5 31.3% 14.2‰ 196 59.0% 45.5‰
 Female
  Normal 149 63.9% 9.3‰ 64 68.1% 3.9‰ 213 65.1% 6.6‰ 181 49.2% 17.7‰ 100 51.0% 20.9‰ 7 50.0% 14.5‰ 107 51.0% 20.3‰
   Low Risk 
Adenomas 17 7.3% 1.1‰ 6 6.4% 0.4‰ 23 7.0% 0.7‰ 41 11.1% 4.0‰ 23 11.7% 4.8‰ 6 42.9% 12.4‰ 29 13.8% 5.5‰
   High Risk 
Adenomas 50 21.5% 3.1‰ 17 18.1% 1.0‰ 67 20.5% 2.1‰ 124 33.7% 12.1‰ 67 34.2% 14.0‰ 1 7.1% 2.1‰ 68 32.4% 12.9‰
  Cancer 17 7.3% 1.1‰ 7 7.4% 0.4‰ 24 7.3% 0.7‰ 22 6.0% 2.2‰ 6 3.1% 1.3‰ 0 0.0% 0.0‰ 6 2.9% 1.1‰
   Advanced 
Neoplasm 67 28.8% 4.2‰ 24 25.5% 1.5‰ 91 27.8% 2.8‰ 146 39.7% 14.3‰ 73 37.2% 15.2‰ 1 7.1% 2.1‰ 74 35.2% 14.0‰
Table 4.  Comparisons of Positive Predictive Values and Detection Rates according to the test used during 
the screening period. Tested: each person is counted once for each test performed. PPV: Positive Predictive 
Value; DR: Detection Rate → Endoscopy result/Screened population.
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Consistent with previous results26,41–44, FIT obtained much better detection rates than gFOBT. HRA detection 
rate never reached the standard value in any round with gFOBT. The introduction of FIT improved the detection 
rate, even among people who had previously participated with gFOBT.
Few programmes show the results according to first or subsequent screening. This is an important variable 
because the results vary depending on whether the individual participates for the first time or has been screened 
previously. Steele et al.45 observed that repeated invitations have a positive effect on participation in both groups 
They found acceptable neoplastic detection rates but, unlike our programme, they found worse cancer stage in 
incidence screenees.
Our programme, additionally, is one that has used both tests. The results of the group that participated with 
both tests can be useful for those programmes that are thinking to change its screening test from gFOBT to FIT 
and have information to the impact that it would suppose (especially the number of additional colonoscopies and 
detection rates).
Most cancers were diagnosed at an early stage, but this indicator did not reach the 70% target marked by 
the Catalan Advisory Group for Cancer Screening17. It is important to note that, in some CRC screening pro-
grammes, carcinomas in situ were included in the cancer group, which may increase the reported rates of early 
stage cancers. In our programme, carcinomas in situ were not considered cancers, but adenomas, with the conse-
quent reduction in the reported rates of early stage cancer.
We consider that achieving a high detection rate for pre-neoplastic lesions is even more relevant than diagnos-
ing early stage cancers. Detecting and removing preneoplastic lesions, stops the progression to cancer, therefore 
reduces the incidence of CRC and its associated mortality, increases survival and improves the quality of life.
Interval cancers should be recorded as a part of the screening process. The HRA detection rate has emerged 
as a potential measure of colonoscopy performance quality that correlates with interval cancer46. Interval cancer 
is a difficult indicator to measure, because of the need for adequate follow-up and a link between endoscopy and 
pathology reports, or cancer registry databases (which are unavailable in many countries as in our region)33,47.
The unknown completeness and accuracy of the central registry of insured could be a limitation. Nevertheless 
this registry was only used to get the target population and therefore, it was only involved in the coverage indica-
tor. All other indicators were obtained from the specific colorectal cancer screening data base, which underwent 
to constant quality controls by the technical office.
Besides enhancing the results of the worst indicators, it is essential to maintain at good degree those with an 
acceptable result. The European guide is a first step for having quality standards of CRC screening programmes 
and allows comparisons between programmes or within the same programme across time, based on the same cri-
teria. The availability of these standards substantially improves data comparisons and the exchange of experience 
between screening programmes in Europe and elsewhere. Nevertheless, further editions should incorporate new 
indicators such as those related with the adverse effects of the screening process as well as related costs.
In conclusion, the programme has identified as a priority to improve participation and to reduce the time 
between a positive FOBT result and the colonoscopy. Our results might point out the need to enhance awareness 
of screening among men (who have the lowest participation rate but the highest detection rates) and people who 
are screened for the first time and overcome participation barriers48.
It is also essential to carefully plan the agendas of colonoscopies needed to achieve the activity within the 
proper interval. The extension of the programme throughout Catalonia will be a reality soon and we must be 
prepared.
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